RESUMO
Clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. We present a patient with a diagnosis of schizoaffective disorder who was stable on clozapine for a decade until discontinuation due to thrombocytopenia. She experienced a relapse of her illness, presenting with psychotic and catatonic features with poor oral intake and physical health complications requiring a lengthy admission to the hospital. There was a poor response to alternative antipsychotics and a full course of electroconvulsive therapy. Intramuscular (IM) clozapine was initiated due to catatonia and refusal to accept oral medications. After receiving 10 doses of IM clozapine, she started accepting oral clozapine and made a full recovery within a few weeks. The low platelet count was persistent, and a bone marrow biopsy showed results consistent with immune thrombocytopenia being the cause of that low platelet count.
Assuntos
Antipsicóticos , Catatonia , Clozapina , Trombocitopenia , Humanos , Clozapina/efeitos adversos , Clozapina/administração & dosagem , Clozapina/uso terapêutico , Trombocitopenia/induzido quimicamente , Trombocitopenia/tratamento farmacológico , Feminino , Catatonia/tratamento farmacológico , Injeções Intramusculares , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Transtornos Psicóticos/tratamento farmacológico , Resultado do Tratamento , Pessoa de Meia-IdadeAssuntos
Catatonia , Hipotireoidismo , Tiroxina , Humanos , Catatonia/tratamento farmacológico , Catatonia/diagnóstico , Hipotireoidismo/tratamento farmacológico , Hipotireoidismo/complicações , Hipotireoidismo/diagnóstico , Tiroxina/uso terapêutico , Diagnóstico Diferencial , Feminino , Adesão à Medicação , Pessoa de Meia-IdadeRESUMO
Symptoms of catatonia include silence, motionlessness, and postural retention. Although it is important to detect and treat catatonia early, before it becomes severe, postoperative cases have inherent risks that hinder diagnosis and treatment. A 60-year-old man with schizophrenia underwent endoscopic/thoracoscopic esophagectomy and was extubated in the operating room. In the intensive care unit (ICU), he had stiffness in the neck, ankles, and knees, catalepsy during passive knee flexion, mild disturbance of consciousness, mild creatine kinase elevation, and respiratory depression. Intravenous diazepam was administered for diagnosis, and the patient's rapid improvement indicated catatonia. He was intubated and started on lorazepam; tapering produced no recurrence of symptoms. The patient was extubated and transferred to the general ward on postoperative Day 2. Because this patient was extubated in the operating room and was managed postoperatively in the ICU with a full-time doctor, his symptoms were easily recognized and early diagnosis was possible. Thus, we were able to administer drug therapy quickly and adequately and perform forward management that accounted for postoperative risks, thereby achieving a favorable outcome.
Assuntos
Catatonia , Diagnóstico Precoce , Lorazepam , Humanos , Masculino , Pessoa de Meia-Idade , Catatonia/diagnóstico , Catatonia/tratamento farmacológico , Lorazepam/administração & dosagem , Lorazepam/uso terapêutico , Esofagectomia , Resultado do Tratamento , Diazepam/administração & dosagem , Esquizofrenia/diagnóstico , Esquizofrenia/tratamento farmacológico , Complicações Pós-Operatórias/diagnósticoRESUMO
OBJECTIVE: Catatonia is a neuropsychiatric disorder associated with changes in behavior and affect. In adults, catatonia can respond rapidly to treatment with benzodiazepines as part of the "lorazepam challenge test." The acute effectiveness of benzodiazepine treatment in pediatric catatonia, however, has received less study. This study reports catatonia severity as measured by the Bush Francis Catatonia Rating Scale (BFCRS) in pediatric patients before and after treatment with lorazepam. METHODS: Multicenter retrospective cohort study from 1/1/2018 to 6/1/2023 of patients aged 18 and younger with a clinical diagnosis of catatonia and assessment using the BFCRS before and after treatment with lorazepam. RESULTS: Among 54 patients, median age was 16, and 26 (48.1 %) were female. Neurodevelopmental disabilities were present in 24 (44.4 %) of patients. Prior to treatment, patients had a mean BFCRS score of 16.6 ± 6.1, which significantly reduced to 9.5 ± 5.3 following treatment with lorazepam (mean paired difference 7.1; t = 9.0, df = 53, p < 0.001), representing a large effect size (Hedges's g = 1.20; 95 % CI: 0.85 to 1.55). No significant association was found between lorazepam dose or route of administration and clinical response, nor were age, sex, study site, the presence of a neurodevelopmental disorder, the presence of hyperactive catatonic features, or the time between treatment and reassessment associated with post-treatment BFCRS. CONCLUSIONS: Lorazepam resulted in a rapid improvement in BFCRS score in pediatric patients, with a large effect size. Further research is needed into optimal dosing and route of administration of the lorazepam challenge test in pediatric patients.
Assuntos
Catatonia , Lorazepam , Humanos , Lorazepam/administração & dosagem , Lorazepam/farmacologia , Lorazepam/uso terapêutico , Feminino , Masculino , Catatonia/tratamento farmacológico , Catatonia/diagnóstico , Estudos Retrospectivos , Adolescente , Criança , Pré-Escolar , Resultado do Tratamento , Índice de Gravidade de DoençaRESUMO
Catatonia is a neuropsychiatric disorder characterized by motor, affective and cognitive-behavioural signs, which lasts from hours to days. Intensive research over the past two decades has led to catatonia being recognized as an independent diagnosis in the International Classification of Diseases, 11th Revision (ICD-11) since 2022. Catatonia is found in 5-18% of inpatients on psychiatric units and 3.3% of inpatients on medical units. However, in an unknown number of patients, catatonia remains unrecognized and these patients are at risk of life-threatening complications. Hence, recognizing the symptoms of catatonia early is crucial to initiate appropriate treatment to achieve a favourable outcome. Benzodiazepines such as lorazepam and diazepam, electroconvulsive therapy, and N-methyl-D-aspartate antagonists such as amantadine and memantine, are the cornerstones of catatonia therapy. In addition, dopamine-modulating second-generation antipsychotics (for example, clozapine and aripiprazole) are effective in some patient populations. Early and appropriate treatment combined with new screening assessments has the potential to reduce the high morbidity and mortality associated with catatonia in psychiatric and non-psychiatric settings.
Assuntos
Benzodiazepinas , Catatonia , Eletroconvulsoterapia , Catatonia/diagnóstico , Catatonia/terapia , Catatonia/fisiopatologia , Catatonia/etiologia , Humanos , Eletroconvulsoterapia/métodos , Benzodiazepinas/uso terapêutico , Lorazepam/uso terapêutico , Antipsicóticos/uso terapêutico , Amantadina/uso terapêutico , Memantina/uso terapêutico , Diazepam/uso terapêuticoAssuntos
Catatonia , Paralisia Cerebral , Eletroconvulsoterapia , Epilepsia , Humanos , Catatonia/terapia , Catatonia/etiologia , Epilepsia/terapia , Epilepsia/complicações , Feminino , Paralisia Cerebral/complicações , Paralisia Cerebral/terapia , Vasculite Associada ao Lúpus do Sistema Nervoso Central/terapia , Vasculite Associada ao Lúpus do Sistema Nervoso Central/complicações , AdultoRESUMO
Malignant catatonia (MC) is a complex, life-threatening condition characterized by motor dysregulation and autonomic instability, which requires prompt and effective treatment. There are some limitations to the current recommendations for treating MC, including barriers to receiving ECT, failure to respond to benzodiazepines, or benzodiazepine intolerance. To the authors' knowledge, there are 3 case reports in the literature describing the use of amantadine in the treatment of MC. We present the case of a 51-year-old female with a history of multiple medical and psychiatric conditions who was admitted to the hospital for altered mental status. During her admission, she developed symptoms that raised concern about MC, which was initially managed with lorazepam. However, due to concerns about severe respiratory compromise, lorazepam was discontinued, and the patient was started on liquid amantadine. She showed marked reduction in the symptoms of malignant catatonia, and the autonomic instability resolved after she was started on amantadine. The patient was eventually discharged home with outpatient follow-up scheduled. Our case report shows successful treatment of MC with liquid amantadine in a patient who was unable to tolerate escalating doses of benzodiazepines. The positive response to amantadine suggests that it may be a useful treatment option for MC. While further studies are needed, clinicians should consider the use of amantadine in the treatment of MC, especially in patients who are unable to tolerate benzodiazepines, who have failed to respond to treatment with benzodiazepines, or who are being treated in institutions where the availability of ECT is limited. Amantadine may be more readily accessible given its multiple formulations and wide availability.
Assuntos
Amantadina , Catatonia , Humanos , Amantadina/administração & dosagem , Amantadina/uso terapêutico , Feminino , Pessoa de Meia-Idade , Catatonia/tratamento farmacológico , Catatonia/etiologia , Dopaminérgicos/administração & dosagem , Lorazepam/administração & dosagem , Lorazepam/uso terapêuticoRESUMO
BACKGROUND: Catatonia, as a transdiagnostic construct, manifests across various psychiatric and non-psychiatric conditions. Understanding how symptom variations impact the catatonia construct and differ across primary diagnoses (schizophrenia, bipolar disorder, unipolar depression, and neurological/metabolic/immunological condition) is essential to refine diagnostic and therapeutic approaches. This study aims to compare the symptom networks and centrality measures of these diagnoses. METHODS: We conducted a network analysis using Bush-Francis Catatonia Rating Scale (BFCRS) data from 118 patients, examining centrality measures and network comparisons across the four primary diagnostic groups. RESULTS: In the general catatonia network, the three most central symptoms identified were Excitement (1.462), Perseveration (1.456), and Impulsivity (1.332). While the overall structure of the catatonia networks did not show significant differences between diagnoses in terms of symptom connections and centrality, variations in centrality measures were observed among the different networks. CONCLUSIONS: The study reinforces the notion of catatonia as an independent syndrome relatively to psychiatric or non-psychiatric diagnoses. However, the variation in centrality of symptoms across different primary diagnoses provides critical insights that could aid clinicians in tailoring diagnostic and therapeutic strategies. Future research should further explore these relationships and develop more refined approaches to managing catatonia.
Assuntos
Catatonia , Catatonia/diagnóstico , Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Transtorno Bipolar/diagnóstico , Escalas de Graduação Psiquiátrica , Adulto Jovem , Esquizofrenia/diagnóstico , Esquizofrenia/complicaçõesRESUMO
Presented clinical observation of anti-NMDA-receptor encephalitis, which was first described in 2007, is rare and to date has not been sufficiently studied. The disease often manifests with psychopathological symptoms and catatonia, so patients are transferred into a mental healthcare institution and often require intensive care and resuscitation, due to the development of life-threatening respiratory and hemodynamic disorders. Diagnosis is based on detection of autoantibodies to the NR1- and NR2 subunits of the glutamate NMDA receptor in blood serum and cerebrospinal fluid. Pathogenesis-based therapy includes the administration of glucocorticoids and intravenous immunoglobulins, plasmapheresis, as well as the introduction of monoclonal antibodies in also used, and in severe cases, cytostatics are prescribed. The widespread comorbidity of anti-NMDA receptor encephalitis with ovarian neoplasms in women (up to 60%) requires appropriate diagnosis and early removal of ovarian neoplasms when they are detected. With timely diagnosis and adequate treatment strategies, the outcome of this rare disorder is usually positive.
Assuntos
Encefalite Antirreceptor de N-Metil-D-Aspartato , Autoanticorpos , Neoplasias Ovarianas , Adulto , Feminino , Humanos , Encefalite Antirreceptor de N-Metil-D-Aspartato/diagnóstico , Encefalite Antirreceptor de N-Metil-D-Aspartato/complicações , Autoanticorpos/sangue , Autoanticorpos/líquido cefalorraquidiano , Catatonia/etiologia , Catatonia/diagnóstico , Imunoglobulinas Intravenosas/uso terapêutico , Transtornos Mentais/etiologia , Transtornos Mentais/diagnóstico , Neoplasias Ovarianas/complicações , Neoplasias Ovarianas/diagnóstico , Plasmaferese , Receptores de N-Metil-D-Aspartato/metabolismoRESUMO
Lithium may cause toxicity as it has a narrow therapeutic range. Lithium intoxication may manifest in the form of acute, acute on chronic and chronic intoxication. Neurotoxicity is a common component of chronic lithium intoxication and the symptoms include tremor, ataxia, dysarthria, extrapyramidal symptoms, hyperreflexia, seizures and status epilepticus. Although rare, catatonia could as a manifestation of lithium neurotoxicity. In this report, we present a patient with bipolar disorder presenting with catatonic symptoms secondary to lithium intoxication. We will discuss the risk factors, differential diagnosis and the treatment of catatonic symptoms. Lithium neurotoxicity may present with various clinical symptoms including catatonia, and differential diagnosis should be made well in such cases. If lithium neurotoxicity is suspected, rapid and appropriate intervention is required to prevent permanent neurological damage. Keywords: Lithium, Neurotoxicity, Catatonia.
Assuntos
Transtorno Bipolar , Catatonia , Humanos , Antimaníacos/efeitos adversos , Transtorno Bipolar/tratamento farmacológico , Catatonia/induzido quimicamente , Diagnóstico Diferencial , Síndromes Neurotóxicas/etiologia , Síndromes Neurotóxicas/diagnósticoRESUMO
Catatonia is a complex syndrome with unique cognitive, psychomotor, and mood features. Mannerisms and stereotypies are catatonic signs that have been extensively observed and described in the literature, mostly in the context of movements or motor acts. Stereotypies are commonly described as repetitive psychomotor or verbal acts with the abnormality not inherent in the act but in its frequency. Mannerisms, like stereotypies, are repetitive psychomotor or verbal acts, but they are fundamentally odd in nature. Recently, several reports have described these phenomena in the context of complex behaviors, such as eating and drinking. Identification and appreciation of personal and cultural norms, in addition to a careful analysis of behavioral processes and actions, are important tools for clinicians to identify these potentially elusive and often missed patterns of behavior in patients with catatonia. We present the case of a 30-year-old male with a psychiatric history of treatment-resistant, recurrent major depressive disorder with psychotic features who presented to the inpatient psychiatric unit with signs of catatonia, including repeated, purposeless eating. The patient's chart was reviewed, and a literature review was conducted using PubMed with the keywords catatonia, stereotypies, mannerisms, and hyperphagia. The patient, who was diagnosed with catatonia and expressed hyperphagia as a stereotypy, responded to lorazepam. This case shows that hyperphagia may present as a stereotypy in patients with catatonia.
Assuntos
Catatonia , Hiperfagia , Humanos , Catatonia/etiologia , Catatonia/tratamento farmacológico , Masculino , Hiperfagia/psicologia , Hiperfagia/etiologia , Adulto , Comportamento Estereotipado , Transtorno Depressivo Maior , Lorazepam/uso terapêutico , Lorazepam/administração & dosagemRESUMO
Electroconvulsive therapy (ECT) is an effective and safe treatment method for many psychiatric disorders. In general medical practice, ECT may cause side effects as most other treatment methods do. Headache, myalgia, nausea, vomiting, confusion, anterograde amnesia are common side effects of electroconvulsive therapy. Fever; in addition to general medical conditions such as infection, malignancy, connective tissue diseases, drug treatments, malignant hyperthermia, convulsions, it can also occur due to conditions such as neuroleptic malignant syndrome (NMS), serotonin syndrome, catatonia, malignant catatonia, which are frequently encountered in psychiatry clinics. In the literature, transient fever response due to electroconvulsive therapy application have been described, albeit rarely. Although there are many proposed mechanisms for the emergence of a fever response, regardless of its cause, it is still not understood why some fever responses occur. In this article, we present the differential diagnosis of the fever response, possible causes, and the mechanisms that may reveal the secondary fever response to electroconvulsive therapy in a case with a diagnosis of catatonic schizophrenia, who developed a fever response during electroconvulsive therapy sessions and no fever response was observed at times other than electroconvulsive therapy sessions. In this case, postictal benign fever response associated with electroconvulsive therapy was considered after excluding other medical conditions that may cause a fever response after electroconvulsive therapy. Keywords: ECT, Fever, Catatonia, NMS.
Assuntos
Catatonia , Eletroconvulsoterapia , Síndrome Maligna Neuroléptica , Esquizofrenia , Humanos , Esquizofrenia Catatônica/complicações , Esquizofrenia Catatônica/terapia , Catatonia/etiologia , Catatonia/terapia , Catatonia/diagnóstico , Esquizofrenia/complicações , Esquizofrenia/terapia , Eletroconvulsoterapia/efeitos adversos , Eletroconvulsoterapia/métodos , Síndrome Maligna Neuroléptica/complicações , Síndrome Maligna Neuroléptica/diagnósticoRESUMO
BACKGROUD: Catatonia encompasses a group of severe psychomotor syndromes affecting patients' motor, speech, and complex behaviors. Common features include rigidity, reduced mobility, speech, sputum production, defecation, and eating. Risks associated with catatonia, such as increased muscle tension and reduced swallowing and coughing reflexes, along with risks from therapeutic approaches like prolonged bed rest and sedative drugs, can elevate the risk of aspiration pneumonia, severe pneumonia, and acute respiratory failure. These complications significantly impede catatonia treatment, leading to poor prognosis and jeopardizing patient safety. CASE DESCRIPTION: In this report, we present a case of catatonia complicated by severe pneumonia and respiratory failure, successfully managed with modified electroconvulsive therapy alongside tracheotomy. We hope this case provides valuable insights for psychiatrists encountering similar scenarios, facilitating the development of rational therapeutic strategies for prompt improvement of patient condition.
Assuntos
Catatonia , Eletroconvulsoterapia , Pneumonia , Insuficiência Respiratória , Humanos , Traqueotomia/efeitos adversos , Catatonia/terapia , Catatonia/tratamento farmacológico , Pneumonia/complicações , Insuficiência Respiratória/complicações , Insuficiência Respiratória/terapiaRESUMO
RATIONALE: Turner syndrome (TS) is a genetic disorder associated with partial or complete monosomy X abnormalities; some patients may have a higher risk of psychiatric symptoms. Catatonia is associated with a wide range of life-threatening complications with complex pathogenesis; However, It very rare for patients with TS to develop psychotic symptoms and eventually progress to catatonia. This case report describes the diagnostic and therapeutic course of catatonia-associated TS. PATIENT CONCERNS: In this study, we report the case of a patient with TS who initially developed sudden hallucinations, delusions, and emotional instability, followed by catatonia. DIAGNOSES: The patient was diagnosed with: unspecified catatonia; TS. INTERVENTIONS: Treatment included administering a combination of esazolam injections and olanzapine tablets, placing a gastric tube and urinary catheter, and providing nutritional support. OUTCOMES: After treatment, the patient's hallucinations, delusions, and catatonia disappeared, with no residual sequelae, and social functioning returned to normal. LESSONS: For patients with TS who present with psychotic symptoms and catatonia, a comprehensive evaluation is necessary, and treatment with antipsychotics and benzodiazepines is effective.
Assuntos
Antipsicóticos , Catatonia , Transtornos Psicóticos , Síndrome de Turner , Humanos , Catatonia/etiologia , Catatonia/terapia , Catatonia/diagnóstico , Síndrome de Turner/complicações , Transtornos Psicóticos/etiologia , Transtornos Psicóticos/tratamento farmacológico , Antipsicóticos/uso terapêutico , Alucinações/complicaçõesRESUMO
BACKGROUND: Catatonia is a highly prevalent syndrome in patients presenting with major neurocognitive disorders (dementia). In this study, we aim to provide a comprehensive description of the clinical and therapeutic aspects of catatonia in patients with dementia. METHOD: This descriptive study, conducted between September 2015 and June 2022, collected data from 25 patients diagnosed with dementia, out of 143 patients treated for catatonia in our specialized psychiatry department. We collected sociodemographic, clinical and treatment data for each patient. RESULTS: Dementia patients constituted 17% of the catatonic cases. Predominantly female, the cohort had a mean age of 65. Diagnoses included Alzheimer's (4 patients, 17%) and Parkinson's (1 patient, 4%) diseases, Lewy body dementia (5 patients, 21%), vascular dementia (4 patients, 17%) and frontotemporal lobar degeneration (10 patients, 41%). The mean Bush-Francis Catatonia Rating Scale score upon admission was 20/69. Overall, complete remission of catatonia was achieved in 75% of patients (n=18), with only 13% (n=3) responding to lorazepam alone, while others required additional interventions such as electroconvulsive therapy (ECT) and/or amantadine. Vascular dementia was predominantly observed in cases resistant to treatment. CONCLUSION: The findings indicate a frequent co-occurrence of catatonia and dementia, highlighting treatability yet suggesting a potential for resistance to lorazepam, which varies by dementia diagnosis. Investigating the mechanisms underlying this resistance and the variability in treatment response is crucial for developing more precise therapeutic strategies.
Assuntos
Catatonia , Demência , Eletroconvulsoterapia , Humanos , Catatonia/terapia , Catatonia/tratamento farmacológico , Catatonia/etiologia , Feminino , Masculino , Idoso , Demência/complicações , Eletroconvulsoterapia/métodos , Pessoa de Meia-Idade , Lorazepam/uso terapêutico , Idoso de 80 Anos ou mais , Comorbidade , Resultado do TratamentoRESUMO
OBJECTIVE: To ascertain the presence of catatonia in cases of pediatric postoperative cerebellar mutism syndrome (PPCMS). METHOD: A systematic review of PPCMS case reports of patients aged 0-17 years with sufficient clinical information to extract catatonic phenomena was undertaken following PRISMA guidelines. Standardized catatonia rating scales were applied to selected cases retrospectively to ascertain whether diagnostic criteria for catatonia were met. A case known to the authors is also presented. RESULTS: Two hundred twenty-one suitable full-text articles were identified. Following screening and application of inclusion criteria, 51 articles were selected plus seven more from their references, reporting on 119 subjects. All cases met Bush and Francis (BF) diagnostic criteria for catatonia, 92.5% Pediatric Catatonia Rating Scale (PCRS), 52.9% ICD-11, and 44.5% DSM-5. All patients presented with mutism. The next most frequent signs were immobility/stupor (77.3%), withdrawal (35.3%), mannerisms (23.5%), and excitement/agitation (18.5%). Most cases presented with stuporous catatonia (75.6%). Catatonia most frequently occurred following resection of medulloblastoma (64.7%). Preoperative hydrocephalus occurred in 89 patients (74.8%). CONCLUSION: Catatonia was frequent in this PPCMS sample, with a predominant stuporous variant; it should be considered in patients with PPCMS and assessed with reliable and validated instruments for prompt diagnosis and management.
Assuntos
Catatonia , Mutismo , Complicações Pós-Operatórias , Adolescente , Criança , Pré-Escolar , Humanos , Lactente , Recém-Nascido , Catatonia/etiologia , Catatonia/diagnóstico , Doenças Cerebelares/complicações , Doenças Cerebelares/cirurgia , Doenças Cerebelares/etiologia , Mutismo/etiologia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/diagnósticoRESUMO
New onset movement disorders are a common clinical problem in pediatric neurology and can be infectious, inflammatory, metabolic, or functional in origin. Encephalitis is one of the more important causes of new onset movement disorders, and movement disorders are a common feature (~25%) of all encephalitis. However, all encephalitides are not the same, and movement disorders are a key diagnostic feature that can help the clinician identify the etiology of the encephalitis, and therefore appropriate treatment is required. Movement disorders are a characteristic feature of autoimmune encephalitis such as anti-NMDAR encephalitis, herpes simplex virus encephalitis-induced autoimmune encephalitis, and basal ganglia encephalitis. Other rarer autoantibody-associated encephalitis syndromes with movement disorder associations include encephalitis associated with glycine receptor, DPPX, and neurexin-3 alpha autoantibodies. In addition, movement disorders can accompany acute disseminated encephalomyelitis with and without myelin oligodendrocyte glycoprotein antibodies. Extremely important infectious encephalitides that have characteristic movement disorder associations include Japanese encephalitis, dengue fever, West Nile virus, subacute sclerosing panencephalitis (SSPE), and SARS-CoV-2 (COVID-19). This chapter discusses how specific movement disorder phenomenology can aid clinician diagnostic suspicion, such as stereotypy, perseveration, and catatonia in anti-NMDAR encephalitis, dystonia-Parkinsonism in basal ganglia encephalitis, and myoclonus in SSPE. In addition, the chapter discusses how the age of the patients can influence the movement disorder phenomenology, such as in anti-NMDAR encephalitis where chorea is typical in young children, even though catatonia and akinesia is more common in adolescents and adults.
Assuntos
Encefalite Antirreceptor de N-Metil-D-Aspartato , Catatonia , Coreia , Transtornos dos Movimentos , Panencefalite Esclerosante Subaguda , Adolescente , Criança , Pré-Escolar , Humanos , Encefalite Antirreceptor de N-Metil-D-Aspartato/complicações , Encefalite Antirreceptor de N-Metil-D-Aspartato/diagnóstico , Autoanticorpos/metabolismo , Transtornos dos Movimentos/etiologia , Panencefalite Esclerosante Subaguda/complicaçõesRESUMO
BACKGROUND: Palliative psychiatry is an emerging field that suggests a role for palliative interventions in the management of severe and persistent mental illness (SPMI). Current literature describes using a palliative approach for patients with severe anorexia nervosa. To our knowledge, this is the first case report describing end-of-life care in a patient with treatment-refractory catatonic schizophrenia. CASE DESCRIPTION: We describe the case of a 49-year-old man with schizophrenia and severe chronic agitated/malignant catatonia who was hospitalized for ten months. Multiple treatment trials including medication such as neuroleptics and benzodiazepines, electroconvulsive therapy, and empiric interventions such as intravenous immunoglobulins were either not tolerated or did not result in clinically significant improvement. The patient continued to intermittently require intubation and sedation to control intractable behavioral and psychiatric disturbances. Ultimately, with collaboration of psychiatry, neurology, ethics, intensive care, and palliative care teams, the patient's parents decided to forgo further diagnostic testing and life-sustaining treatments. The patient died weeks later of aspiration pneumonia with good symptom control. CONCLUSIONS: This case permits discussion of palliative interventions in patients with SPMI such as treatment-refractory psychotic disorders who likely cannot achieve a quality of life that is acceptable to them. Here, it can be justified to prioritize relief of suffering and prevention of further burdensome interventions over treatment of the SPMI symptoms such as catatonia and even over keeping the patient alive.
Assuntos
Catatonia , Psiquiatria , Esquizofrenia , Masculino , Humanos , Pessoa de Meia-Idade , Catatonia/diagnóstico , Catatonia/tratamento farmacológico , Esquizofrenia/terapia , Esquizofrenia/tratamento farmacológico , Esquizofrenia Resistente ao Tratamento , Qualidade de Vida/psicologiaRESUMO
Catatonia is a well characterized psychomotor syndrome combining motor, behavioural and neurovegetative signs. Benzodiazepines are the first-choice treatment, effective in 70 % of cases. Currently, the factors associated with benzodiazepine resistance remain unknown. We aimed to develop machine learning models using clinical and neuroimaging data to predict benzodiazepine response in catatonic patients. This study examined a cohort of catatonic patients who underwent standardized clinical evaluation, 3 T brain MRI, and benzodiazepine trial. Based on clinical response, patients were classified as benzodiazepine responders or non-responders. Cortical thickness and regional brain volumes were measured. Two machine learning models (linear model and gradient boosting tree model) were developed to identify predictors of treatment response using clinical, demographic, and neuroimaging data. The cohort included 65 catatonic patients, comprising 30 benzodiazepine responders and 35 non-responders. Using clinical data alone, the linear model achieved 63% precision, 51% recall, a specificity of 61%, and 58% AUC, while the gradient boosting tree (GBT) model attained 46% precision, 60% recall, a specificity of 62% and 64% AUC. Incorporating neuroimaging data improved model performance, with the linear model achieving 66% precision, 57% recall, a specificity of 67%, and 70% AUC, and the GBT model attaining 50% precision, 50% recall, a specificity of 62% and 70% AUC. The integration of imaging data with demographic and clinical information significantly enhanced the predictive performance of the models. The duration of the catatonic syndrome, along with the presence of mitgehen (passive obedience) and immobility/stupor, and the volume of the right medial orbito-frontal cortex emerged as important factors in predicting non-response to benzodiazepines.